Direkt zum Inhalt
Merck

Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2015-04-07)
Ramya Kumareswaran, Naz Chaudary, Karolina Jaluba, Alice Meng, Jenna Sykes, Asm Borhan, Richard P Hill, Robert G Bristow
ZUSAMMENFASSUNG

Solid tumors contain regions of chronic and cyclic hypoxia. Chronic hypoxia can downregulate RAD51 and sensitize cells to PARP inhibition. Herein, we show that RAD51 expression, cell survival and toxicity to PARP inhibition is not affected under cyclic hypoxic conditions. This suggests that PARP inhibition may be selectively toxic in tumor sub-regions associated with chronic hypoxia.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Propidiumjodid, ≥94.0% (HPLC)
Sigma-Aldrich
Propidiumjodid -Lösung
Sigma-Aldrich
2,2′-Bichinolin-4,4′-dicarbonsäure Dinatriumsalz Dihydrat, ≥98% (HPLC)